CYP3A5 and tuberous sclerosis: However, it was interesting in our previous study that the initial dosage recommendation for sirolimus in children with TSC, CYP3A4, and CYP3A5 polymorphism did not significantly affect sirolimus clearance rates (Wang et al., 2020).